A clinical trial has found that treatment with the immunomodulator interferon beta-1a plus the antiviral remdesivir was not superior to treatment with remdesivir alone in hospitalized adults with COVID-19 pneumonia. In addition, ...
Oct 18, 2021
0
54
Donald Trump's brief stay in hospital in early October raised awareness—once again—of the variety of treatments being investigated for COVID-19.
Oct 22, 2020
0
4
A European clinical trial involving some 3,200 people has been launched to test four possible experimental treatments against the coronavirus.
Mar 22, 2020
0
311
Researchers from the University of British Columbia and Vancouver Coastal Health Research Institute have found that a widely prescribed drug for multiple sclerosis (MS) is associated with longer survival for patients.
Mar 18, 2019
0
438
A newfound genetic regulatory mechanism may shape the immune system's ability to fight viral infections, and play a key role in autoimmune diseases that occur when immune cells attack bodily tissues.
Nov 27, 2018
0
112
The human heart is particularly vulnerable to viruses. That's because cardiac myocytes, the heart muscle cells that give your heart its ability to "beat," have one major weakness – they don't reproduce themselves to repair ...
Sep 29, 2017
0
36
Since its approval in 2011, the multiple sclerosis drug fingolimod (Gilenya) has already undergone three early benefit assessments, all of which were mainly based on the approval study TRANSFORMS. After a new modification ...
Mar 08, 2016
0
9
Pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) reassessed fingolimod (trade name: Gilenya), a drug for the treatment ...
Jul 06, 2015
0
11
A new study led by investigators at Brigham and Women's Hospital (BWH) reports the discovery of a genetic variant that is associated with a patient's likelihood of responding to interferon-beta, one of the medications used ...
May 14, 2015
0
93
The immunosuppressive drug fingolimod (trade name: Gilenya) was approved for an expanded therapeutic indication in May 2014: It is now also available for adults with highly active relapsing remitting multiple sclerosis (RRMS) ...
Oct 10, 2014
0
0
